Cerebral vasculopathy in childhood neurofibromatosis type 2: cause for concern?
| Autor: | Shazia K. Afridi, Vijeya Ganesan, Cheryl Hemingway, Karine Lascelles, Rosalie E. Ferner, Ata Siddiqui |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Pediatrics
medicine.medical_specialty Bevacizumab medicine.diagnostic_test business.industry Magnetic resonance imaging medicine.disease Haemorrhagic stroke Magnetic resonance angiography 03 medical and health sciences 0302 clinical medicine Increased risk Developmental Neuroscience 030220 oncology & carcinogenesis Vestibular Schwannomas Pediatrics Perinatology and Child Health otorhinolaryngologic diseases medicine Neurology (clinical) Neurofibromatosis Neurofibromatosis type 2 business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Developmental Medicine & Child Neurology. 60:1285-1288 |
| ISSN: | 0012-1622 |
| DOI: | 10.1111/dmcn.13920 |
| Popis: | Unlike adult neurofibromatosis type 2 (NF2), which presents with symptoms related to bilateral vestibular schwannomas, children with NF2 most frequently present with ocular, dermatological, and neurological symptoms. Arteriopathy, a well-established feature in neurofibromatosis type 1, is not a widely recognized feature of NF2. Here we report three children with NF2 with cerebral arteriopathy and/or arterial ischaemic stroke. Bevacizumab, a vascular endothethial growth factor inhibitor, is an established treatment for rapidly growing vestibular schwannomas; however, it carries a risk of both ischaemic and haemorrhagic stroke. Thus, the role of screening and risk to benefit ratio of bevacizumab in NF2 merit further consideration. WHAT THIS PAPER ADDS: Children with neurofibromatosis type 2 (NF2) may be at increased risk of cerebral vasculopathy and arterial ischaemic stroke. Targeted magnetic resonance angiography should be performed in children with NF2 who are being considered for bevacizumab therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text